Showing posts with label New England Journal of Medicine. Show all posts
Showing posts with label New England Journal of Medicine. Show all posts

Friday, January 25, 2013

Breast cancer screening saves lives: study

Posted: 30 October 2012

Breast cancer x-ray (posed picture)
PARIS: The benefits of preemptive breast cancer screening outweigh the risks, a study said Tuesday, insisting the practice saves thousands of lives.

The new research adds to the debate about the dangers of overdiagnosis, which sees some women undergo invasive treatment for cancers that would never have made them ill or even been diagnosed were it not for the scans.

"Breast screening extends lives," concluded a panel of researchers in The Lancet medical journal.

The team had analysed data from other trials conducted over many years in Britain, where women aged 50 to 70 are invited for a screening mammogram every three years.

The data, it said, pointed to a 20 per cent reduction in mortality -- or one death prevented for every 180 women screened.

This meant that the UK screening programmes "probably prevent about 1,300 breast cancer deaths every year," said the report.

But there is a cost.

Nearly 20 per cent of breast cancer diagnosed by screening would never have caused any problems, said the study.

The panel, set up to advise British policymakers, estimated that among every 10,000 women invited to screening from the age of 50 in the Britain, 681 cancers would be discovered, of which 129 would be overdiagnoses, and 43 deaths prevented.

The report showed that "the UK breast-screening programme extends lives and that, overall, the benefits outweigh the harms," The Lancet wrote in an editorial.

"Women need to have full and complete access to this latest evidence in order to make an informed choice about breast cancer screening."

The team conceded there were limitations to its work, including that all the data scrutinised was more than 20 years old.

Cancer experts have been at loggerheads for years about whether the benefits of screening outweigh the harm of overdiagnosis.

All cancer, once picked up in the screening process, is treated, often with surgery as well as radio- and chemotherapy, as it is impossible to tell which growths would have remained undetected for the remainder of a woman's life.

In August, medical experts Steven Woloshin and Lisa Schwartz wrote in the British Medical Journal (BMJ) that screening only narrowly decreased risks that a 50-year-old woman would die from breast cancer within 10 years -- from 0.53 per cent to 0.46 per cent.

Up to half of women screened annually over 10 years experienced at least one false alarm that required a biopsy, they said.

And in 2010, a report in the New England Journal of Medicine said mammograms have only a "modest" impact on reducing breast cancer deaths.

The latest panel had been created by the national cancer director for England, Mike Richards and Cancer Research UK chief executive officer Harpal Kumar.

Its work, said The Lancet, "should begin to lay the benefits versus harm controversy to rest".

- AFP/ck


-----
Taken from ChannelNewsAsia.com; source article is below:
Breast cancer screening saves lives: study

Enhanced by Zemanta

Aspirin helps fight some colorectal cancers: US study

Aspirin, I could say, is the 'drug' of the century: I've known it since I was young and my parents were taking this pill, and now am old, and it is still a current item, appearing now and then in the news, local and abroad...
-----

Posted: 25 October 2012
Aspirin. (AFP/Getty Images/File - Tim Boyle)
WASHINGTON: Aspirin can help prolong the life of patients suffering from colorectal cancer tumours with a specific genetic mutation, according to a new study released Thursday.

The study of 900 patients carried out by the Dana-Farber Cancer Institute -- an affiliate of Harvard Medical School -- found that the painkiller produced a "sharp jump in survival" among certain patients.

"For patients whose tumours harboured a mutation in the gene PIK3CA, aspirin use produced a sharp jump in survival," with 97 percent of those who took aspirin still alive after five years, compared with 74 percent who did not take it, researchers said.

The drug had no impact on survival rates among patients without a PIK3CA mutation, they added, in a news release accompanying the publication of the study in the New England Journal of Medicine.

"For the first time we have a genetic marker that can help doctors determine which colorectal cancers are likely to respond to a particular therapy," said lead author Shuji Ogino, of the Harvard School of Public Health.

He added that more research must be done before the findings can be considered definitive.

Some 20 percent of colorectal cancer patients have tumours with the mutation, the study said, adding that patients without the mutation can take aspirin, but it can sometimes lead to gastrointestinal ulcers and stomach bleeding.

Colorectal cancer is one of the world's deadliest diseases. The National Cancer Institute expects some 140,000 Americans to be diagnosed with the disease and some 50,000 to die from it this year alone.

- AFP/lp


-----
Taken from ChannelNewsAsia.com; source article is below:
Aspirin helps fight some colorectal cancers: US study

Enhanced by Zemanta

Friday, February 24, 2012

First gene-link to inherited prostate cancer

Posted: 12 January 2012

Genetic sample test. (AFP Photo/Getty Images/Justin Sullivan)
WASHINGTON - US researchers said Wednesday they have found the first genetic mutation linked to an inherited form of prostate cancer, raising new hope of one day improving early screening for the disease.

The mutation appears only in a small subset of prostate cancer patients, but those who inherited it showed 10 to 20 times higher risk of developing prostate cancer, particularly before age 55, the researchers said.

The advance, described in the New England Journal of Medicine, comes amid a two-decade search for clues about the genetic origins of prostate cancer, the most commonly diagnosed male cancer with 240,000 new US cases each year.

Other attempts to isolate particular gene links to prostate cancer have shown mixed results.

"This is the first major genetic variant associated with inherited prostate cancer," said co-author Kathleen Cooney, professor of internal medicine and urology at the University of Michigan Medical School.

The mutation of the HOXB13 gene is believed rare in the general population - only one percent of men are thought to carry it - but among those who do, the risks of developing prostate cancer while young may skyrocket.

"The mutation is significantly more common in men with a family history of prostate cancer that strikes at an earlier age, compared to older patients with no family history," said University of North Carolina scientist Ethan Lange, who was part of the research team.

While more study is needed, scientists hope the finding could lead to genetic tests for men at high risk for prostate cancer, much the same way as women with family history of breast cancer may get tested for the BRCA1 and BRCA2 genes.

"Still, our results strongly suggest this is the most clinically important mutation identified for prostate cancer to date," said Lange.

For this study, researchers honed in on a certain chromosome region, 17q21-22, using samples from young patients with prostate cancer from 94 families who had taken part in studies at the University of Michigan and Johns Hopkins University.

Using the latest technology, they sequenced the DNA of more than 200 genes in that chromosome region and found that four separate families had the same mutation in the HOXB13 gene.

The gene is crucial during fetal development of the prostate and the gland's function in later life.

Of the total 5,100 men scanned, 72 were found to have the mutation, or about 1.4 percent of subjects studied.

In a control group of 1,400 men without prostate cancer, researchers found only one who carried the mutation.

Two different mutations on the same gene were found in families of African descent, but since very few of the participants were black, more research is needed to determine the significance of those.

"It's what we've been looking for over the past 20 years," said co-author William Isaacs, professor of urology and oncology at the Johns Hopkins University School of Medicine.

"It's long been clear that prostate cancer can run in families, but pinpointing the underlying genetic basis has been challenging and previous studies have provided inconsistent results."

Prostate cancer kills about 32,000 men in the United States each year, according to the National Cancer Institute. Hereditary prostate cancer accounts for 10 to 15 percent of all cases.

African-Americans are twice as likely to die from prostate cancer as whites. The disease is common in North America and northwestern Europe, but less so in Asia and South America.

"Previous research has identified multiple genetic foci that appear to be associated with an increase risk of prostate cancer, but the identification of a specific prostate cancer gene has been challenging," said Manish Vira, a urologist at the North Shore-Long Island Jewish Health System, who was not part of the study.

"Just as in patients with breast cancer and the BRCA gene, one could envision a future in which a man with a family history of prostate cancer is screened for this particular mutation, and if positive, would begin early screening as he would be at risk for early onset prostate cancer."

- AFP/al



Taken from ChannelNewsAsia.com; source article is below:
First gene-link to inherited prostate cancer


Enhanced by Zemanta

Tuesday, January 10, 2012

Single gene links rare cancers

One of a kind, that's what this is!
-----

Posted: 22 December 2011

Researcher with test tube of sample
WASHINGTON - Canadian researchers have discovered that a common gene links a number of rare reproductive cancers, a finding that could lead to new approaches for treatment, said a study published on Wednesday.

Ovarian, uterine and testicular cancer were all found to have the same mutation in a gene called DICER, said the research in the New England Journal of Medicine.

Scientists have known about DICER for many years, but its exact role in sparking tumour cells to grow has been unclear.

When the gene mutates, DICER's function is changed "so that it participates directly in the initiation of cancer, but not in a typical 'on-off' fashion," said co-author Gregg Morin, a lead scientist from the Michael Smith Genome Sciences Centre at the British Columbia Cancer Agency.

"DICER can be viewed as the conductor for an orchestra of functions critical for the development and behavior of normal cells," explained co-author Gregg Morin, a lead scientist from the Michael Smith Genome Sciences Centre at the British Columbia Cancer Agency.

"The mutations we discovered do not totally destroy the function of DICER, rather they warp it - the orchestra is still there but the conductor is drunk."

Researchers are examining whether DICER plays a role in other cancers, and will investigate if mutant DICER can be manipulated to treat the cancers it causes.

Ovarian cancer kills about 15,000 women in the United States each year, and about 22,000 new cases are diagnosed annually.

More than 46,000 cases of uterine cancer and 8,100 deaths arise each year in the United States. Testicular cancer is more rare, with 8,300 new cases per year and 350 US deaths, according to the American Cancer Society.

"This breakthrough will be of interest to both the clinical and the fundamental science communities," said Phillip Sharp, Institute Professor at the Massachusetts Institute of Technology and co-winner of the 1993 Nobel Prize in Physiology and Medicine for the discovery of the structure of genes.

"Huntsman, Morin and colleague's very exciting discovery of specific mutations in DICER, a factor essential for syntheses of small regulatory RNAs in ovarian and other human tumors, could lead to new approaches to treatment."

- AFP/al


-----
Taken from ChannelNewsAsia.com; source article is below:
Single gene links rare cancers

Enhanced by Zemanta

Sunday, November 27, 2011

'Promising' step for world's first malaria vaccine

A month later, and is the promising holding up?
-----

Posted: 19 October 2011


Vaccination
WASHINGTON: The search for the world's first malaria vaccine received a boost Tuesday with the release of early results from a major clinical trial showing it cut risk by about half in African children.

The vaccine known as RTS,S is made by the British pharmaceutical giant GlaxoSmithKline's lab in Belgium, and is the first of its kind to attempt to block a parasite, rather than bacteria or viruses.

Experts hailed the phase III trial under way at 11 sites in sub-Saharan Africa as a promising step toward eradicating the ancient mosquito-borne disease that kills almost 800,000 people yearly, most of them children.

The results are published online in the New England Journal of Medicine, and were simultaneously announced at the Malaria Forum hosted by the Bill & Melinda Gates Foundation in Seattle, Washington.

In a statement, philanthropist and Microsoft tycoon Bill Gates described the findings as a "huge milestone" in the fight against malaria, that "has the potential to protect millions of children and save thousands of lives."

Children aged five to 17 months who received three doses of the vaccine saw a 56 per cent lower risk of developing clinical malaria, which causes high fever and chills, according to the study.

When it came to severe malaria -- the stage of the illness that can be fatal and reaches the blood, brain or kidneys -- those who received the vaccine showed a 47 per cent lower risk.

"This is remarkable when you consider that there has never been a successful vaccine against a human parasite," said Tsiri Agbenyega, who chairs the RTS,S Clinical Trials Partnership and heads malaria research at Komfo-Anokye Teaching Hospital in Kumasi, Ghana.

"While these results are encouraging, we still have a ways to go," he told reporters.

The analysis was done with data from 6,000 children in the trial over a 12-month follow up after vaccination.

More data is needed from the younger age group -- infants aged six to 12 weeks -- to better assess how well it works in this particularly vulnerable group, experts said. Additional results from the younger set are due next year.

The World Health Organization says malaria claimed 781,000 lives in 2009. About 90 per cent of malaria deaths each year occur in Africa and 92 per cent of those are children less than five years old.

Asked whether the Gates Foundation would get behind a vaccine with a success rate of only about half, Regina Rabinovich, director for infectious diseases at the foundation's global health program, was circumspect.

"This is a key question. The group will ultimately want to understand efficacy, duration and safety," she said, adding she was "enthusiastic" about the results so far and was awaiting further data.

More than 15,000 children in seven African countries are enrolled in the trial, which is set to continue for two more years, and covers areas with other interventions in place against malaria, such as bed nets and spraying.

RTS,S was created in 1987 in GlaxoSmithKline Biologicals' lab in Belgium. Testing began on healthy adults in Europe and the United States in 1992, before the first Africa study started in Gambia in 1998.

Trial sites are now located in Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania, including 15,460 infants and young children in what GSK described as "the largest malaria vaccine trial to date."

The vaccine works by triggering the immune system to defend the body against Plasmodium falciparum, the deadliest type of malaria parasite.

Side effects included fever and swelling at injection site, "what you would typically see in other childhood vaccinations," said Agbenyega.

Several questions remain, including how the long the vaccine may last and how much it will cost, said Seth Berkley, CEO of the Global Alliance for Vaccines and Immunization (GAVI Alliance).

Malaria "is a huge problem for the poorest of the poor, and there has been a search for vaccines for as long as I can remember," he told AFP. "So to have success, even if not perfect, is a really big deal."

The US Centers for Disease Control and Prevention hailed the findings as "a promising advance in development of a malaria vaccine for African children."

GlaxoSmithKline CEO Andrew Witty said the company had already invested US$300 million to develop the vaccine and aims to produce it at a low cost with no profit, though he said it was too early to set a price.

"We are hopeful that we will be able to bring this vaccine to children in Africa by 2015," Witty said.

- AFP/ck



Taken from ChannelNewsAsia.com; source article is below:
'Promising' step for world's first malaria vaccine

Enhanced by Zemanta

Sunday, May 15, 2011

Macular Degeneration 'effective' drug found

Hopefullly, this drug really is effective, and affordable even more.
-----

08 May 2011

WASHINGTON: The anti-cancer drug Avastine is as effective in fighting macular degeneration as Lucentis, which, however is 40 times more expensive than the cancer fighting medicine, according to results of clinical trials published in the United States.

The study compares Avastine (bevacizumab) to Lucentis (ranibizumab), which both have been developed by US firm Genentech, owned by Swiss laboratory Roche.

During the trials, scientists randomly assigned 1,208 patients with neovascular macular degeneration -- a condition that leads to the gradual loss of central vision -- to receive injections in the eye of ranibizumab or bevacizumab on either a monthly schedule or as needed with monthly evaluation.

"At one year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule," reported the authors of the study, including Doctor Juan Grunwald from the University of Pennsylvania.

"Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizumab administered monthly."

However, the costs of the treatments were vastly different.

The average cost in the ranibizumab group per patient was $23,400 compared to $385 per patient in the bevacizumab group, the researchers said.

The study appears in the latest issue of The New England Journal of Medicine.

-AFP/wk



Taken from ChannelNewsAsia.com; source article is below:
Macular degeneration: "effective" drug found

Enhanced by Zemanta

Monday, April 18, 2011

Angioplasty is safe alternative to bypass surgery: study

And on surgical operations...
-----

Posted: 05 April 2011

Surgeons perform heart surgery.
NEW ORLEANS : People who suffer from serious heart disease could benefit similarly from balloon angioplasty as from major open heart surgery, said a study released by South Korean researchers on Monday.

Bypass surgery, in which vessels are taken from elsewhere in a patient's body and sewn onto the heart to replace clogged ones, is the most common method of treating people with left main coronary artery disease.

But the results of the randomised clinical trial of 600 patients who received either angioplasty or bypass surgery showed similar survival rates and about the same number of major adverse events like heart attack and stroke after one year.

Doctors have long debated which method is best for treating the narrowing of the arteries that is the major cause of heart attacks. Angioplasty is less invasive but can require more repeat procedures if the artery restricts again over time.

"In spite of higher revascularisation after angioplasty, it can be a potential alternative if the two treatments have a similar risk of hard end-points, such as heart attack, death or stroke," said Seung-Jung Park, lead study author.

"At the time this study was initiated, there was great enthusiasm about the outcomes of angioplasty, and as a result, off-label use rapidly spread without enough evidence. Therefore, initiation of a randomised study was urgent."

The PRECOMBAT trial's findings were presented at the American College of Cardiology conference in New Orleans. The study is also being simultaneously published in the New England Journal of Medicine.

The randomised study used a primary outcome measure combining four factors to measure safety and efficacy: death from any cause, heart attack, stroke, and ischemia-driven TVR (target vessel revascularisation), or the need for more treatment after renarrowing.

Death, heart attack and stroke rates were similar among the two groups.

Nine percent of patients in the angioplasty group experienced ischemia-driven TVR after two years, compared to 4.2 percent in the bypass group.

"The incidences of death, heart attack and stroke - which are indicators of safety and have a significant impact on mortality - were comparable," said Park.

"Although angioplasty did have a higher risk of TVR, this efficacy end-point does not have a direct association with mortality and thus has a less significant implication than the safety outcomes," he added.

"Therefore we can conclude that angioplasty can be a feasible alternative to CABG (coronary artery bypass)."

- AFP/al



Taken from ChannelNewsAsia.com; source article is below:
Angioplasty is safe alternative to bypass surgery: study

Enhanced by Zemanta

Sunday, April 17, 2011

New drug hope for hepatitis C sufferers

I'm getting closer to my posting on the publication of the articles, but I sure don't want to get too close that I may overtake the actual publications...

Here's one about hepatitis C; it's a good one.

Read on...
-----

Posted: 31 March 2011

Boceprevir, developed by Merck, is undergoing review before being approved for general use. (AFP/Getty Images/File/Chris Hondros)
WASHINGTON: A cocktail of three drugs, including a new class of antiviral agent, has shown encouraging results in treating hepatitis C, a disease which attacks the liver, a study said on Wednesday.

"This study represents a remarkable advance and a potential cure for people with hepatitis C who have not responded to previous therapy," said co-author Stuart Gordon, from the Henry Ford Hospital in Detroit.

"This study ushers in a new era of drug development that will provide a host of antiviral agents to treat hepatitis C, and we are now witnessing dramatic and rapid advances in how we will be able to treat these patients."

The results published in the March 31 edition of the New England Journal of Medicine reveal the effectiveness of a drug called boceprevir in treating hepatitis C, a chronic viral disease affecting some 3.2 million Americans.

In the past the disease could be spread through contact with infected blood products, and is still contracted by drug users sharing needles or straws during the use of cocaine, or by unprotected sex with a sufferer.

There is currently no vaccine for the hepatitis C virus, and the Centres for Disease Control and Prevention estimates that more than 12,000 people die each year of liver disease and liver cancer associated with the illness.

Most people infected with the disease live symptom-free for years, but once it is discovered it is often too late for it to respond to the current two-drug treatment.

In the study, more than 1,000 patients from several countries including the United States and Canada were divided into three groups.

All three groups received the current two-drug treatment of peginterferon and ribavirine (Rebetol) for four weeks.

One control group then continued to take the same treatment for another 44 weeks, a second group added boceprevir to the two other drugs for 32 weeks, and a third group took the three-drug cocktail for 44 weeks.

The two groups which received doses of boceprevir showed a better response, and in some cases the virus even disappeared from their blood.

Boceprevir specifically targets the hepatitis C virus and inhibits it from replicating in the patient's body. In group two, 59 percent of patients responded to the treatment and in group three in 66 percent.

A virological response is generally taken to mean the virus has been wiped out from the patient's body.

Boceprevir, which has been developed by Merck, is currently undergoing review before being approved for general use by the Food and Drug Administration.

- AFP/de



Taken from ChannelNewsAsia.com; source article is below:
New drug hope for hepatitis C sufferers

Enhanced by Zemanta

Sunday, March 6, 2011

Surgery in the womb works best for spina bifida

Could this be something good, and is focused towards the preservation of mankind? This is encouraging, in contrast to many other findings and discoveries that laments the deterioration of our health, such as smoking, unhealthy foods, illness due to modernization and technology, etc., etc.

But this one is promising, and it is focused right at the start of life...
-----

Posted: 10 February 2011


WASHINGTON: Surgery to repair a birth defect known as spina bifida is best done in the womb rather than after the baby is born, the results of an eight-year US trial released Wednesday suggest.

The method was so successful in boosting babies' health and mobility that the trial was halted early, said the findings published in the New England Journal of Medicine.

Spina bifida is a disorder of the central nervous system that occurs when the spinal cord is partially exposed, protruding on the baby's back.

Children may be paralyzed or may need braces in order to walk, and they may also experience loss of bladder and bowel function.

Many of the babies who have a severe form, known as myelomeningocele, also have a brain stem defect that causes a buildup of spinal fluid in the brain and requires a permanent shunt to drain it.

Typically doctors wait until after the child is born to do surgery. But prenatal surgery can be done at up to 26 weeks gestation, with doctors performing a sort of early Cesarean section to lift the uterus out of the woman's body.

With both mom and fetus under general anesthesia, the uterus is cut open, and an obstetrician positions the fetus's back to the opening so surgeons can stitch it up while the fetus stays inside the uterus.

"The fetus gets an additional shot of muscle relaxant and narcotic," to be sure it is anesthetized, according to Scott Adzick, chief of pediatric surgery at the Children's Hospital of Philadelphia.

"And then the pediatric neurosurgeon does the same type of layered repair before birth that is done after birth to protect the exposed spinal cord."

By operating before the child is born, doctors saw fewer buildups of brain fluid, better motor skills and greater likelihood that the children would eventually be able to walk without braces.

"The damage to the spinal cord and nerves is progressive during pregnancy, so there's a rationale for performing the repair by the 26th week of gestation, rather than after birth," said study co-author Leslie Sutton of the Children's
Hospital of Philadelphia.

Children were evaluated at one year of age and again at age two and a half. At 12 months, just 39.7 percent of the prenatal surgery group needed a shunt compared to 82.5 percent in the postnatal group.

At 30 months of age, children who had the surgery in the womb performed better in mental development and motor skills, with 41.9 percent able to walk without crutches or braces compared to 20.9 percent in the postnatal group.

The Management of Myelomeningocele Study (MOMS) study, a randomized clinical trial, was meant to enroll 200 pregnant mothers but was stopped about two months ago at 183.

"This is the first time a randomized clinical trial has clearly demonstrated that surgery before birth can improve the outcome for patients," said the study.

However, doctors noted that the procedure carried heavy risks, including premature birth, and did not work for all patients.

Two fetuses died in the prenatal surgery group -- one in the womb and one after being born very prematurely at 25 weeks.

Two babies in the postnatal repair group also died, and those deaths were attributable to their spinal malformations, doctors said.

Eighty percent of fetuses who underwent prenatal surgery were born premature -- at an average of 34 weeks compared to 37 weeks in the postnatal group -- and 20 percent showed breathing problems upon being born.

Mothers who underwent the procedure would be forced to have any future deliveries by C-section to avoid uterine rupture.

"Even though the children who underwent the surgery while in the uterus did much better overall, these risks both to the fetus and the mother cannot be ignored," said Diana Farmer, chief surgeon of Benioff Children's Hospital at
the University of California San Francisco.

The study also noted that the initial location of the spinal malformation had an important impact on the children's ability to walk, regardless of when they had the surgery.

National Institutes of Health funding will allow for the children to be monitored between the ages of six and nine to see if there are lasting effects.

Doctors said the highly specialized procedure has been performed at UCSF and Philadelphia children's hospitals, and may soon be offered at hospitals in Michigan, Texas and Ohio.

Spina bifida affects about 1,500 babies born each year in the United States. Folic acid supplements of 400 micrograms daily are recommended for all women of childbearing age to protect against it.

-AFP/jl


Taken from ChannelNewsAsia.com; source article is below:
Surgery in the womb works best for spina bifida



Enhanced by Zemanta

Thursday, January 27, 2011

Faulty Study: Mental Health on Abortion

Crosses Memorialize Abortion 1Image by Vincent J. Brown via FlickrThis is what I am looking for. It has shown itself, just in time...
-----

By Stephanie Samuel|Christian Post Reporter

The president of a post-abortive group disagreed with a study from Denmark that asserts that abortion does not increase the risk of metal health problems in women.

Georgette Forney, a co-founder of Silent No More Awareness Campaign, criticized the study for not going deeper to find the true mental health issues that result for abortion. “They didn’t address the women who may be feeling depressed but don’t go into a hospital,” said Forney, also the president of Anglicans for Life.
The Danish study following post-abortive women between the years 1995 and 2007 concluded that having an abortion does not increase the risk of mental health problems.
The study conceded, however, that anxiety, stress and depression were common among those who sought help. However, researchers found only 15 women per 1,000 needed psychiatric counseling in the study’s 13-year time period.
"A woman should know that her risk of having a psychiatric episode is not increased" after an abortion, asserted Trine Munk-Olsen of Aarhus University, who led the study.
Researchers sampled 84,620 teenagers and women who had an abortion. They determined the women’s mental health status by following the women in various national registries to track admission to mental health counseling at a hospital or outpatient facility before and after an abortion.
But Forney said many women who are not hospitalized for mental health issues feel shame or guilt. Silent No More allows many of these post-abortive women to share their stories at rallies. Women who testify during rallies commonly reported feeling deep sorrow, remorse and regret. Those feelings, Forney stated, often keep women from seeking professional help.
“I think it is a kind of self-punishment,” she remarked.
Forney said of her own abortion that she felt she had to deal with the pain and emotion on her own since she had been the one who chose the procedure.
She also noted that post-abortive women cope with their decisions in different ways.
“God didn’t make us vanilla. Everyone doesn’t manifest [grief] the same way,” she said. Forney said she has seen women display eating disorders, drug and substance abuse, and birth date blues. Often, women dismiss those symptoms and their connections to the abortions, she noted.
Overall, Forney said, “This study does a disservice to women because what do the women [with] depression setting in do.”
“I spend hours and hours and hours on the phone with women crying.”
Researchers of the Danish study noted that women who seek abortions come from a demographic group more likely to have emotional problems to begin with. But Forney doesn’t expect abortion providers to screen women for emotional problems in the near future.
The abortion industry, she said, is a business that uses studies like these to “put abortion before women’s health” and assure women there are no risks associated with the procedure.
However, when women become traumatized, “Nobody wants to deal with their pain.”
Denmark legalized abortion in 1973, the same year the U.S. Supreme Court decided to legalize abortion in the case of Roe v. Wade. The European country had about 13 abortions per 1,000 women in 2008. By comparison, the United States had almost 20 abortions per 1,000 U.S. women that same year, according to the Guttmacher Institute.

Taken from The Christian Post; source article is below:
Woman Who Had Abortion Finds Fault with Positive Abortion Study


Enhanced by Zemanta